DTIL RSI Chart
Last 7 days
16.1%
Last 30 days
7.3%
Last 90 days
4.2%
Trailing 12 Months
-43.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 57.5M | 0 | 0 | 0 |
2023 | 30.6M | 46.5M | 52.3M | 48.7M |
2022 | 102.5M | 37.5M | 20.8M | 25.1M |
2021 | 33.6M | 101.4M | 118.0M | 115.5M |
2020 | 23.8M | 19.5M | 22.0M | 24.3M |
2019 | 14.8M | 18.3M | 20.7M | 22.2M |
2018 | 0 | 0 | 0 | 10.9M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 08, 2024 | kelly john alexander | acquired | 100,008 | 12.00 | 8,334 | chief financial officer |
May 08, 2024 | smith j. jefferson | acquired | 9,996 | 12.00 | 833 | chief research officer |
May 08, 2024 | amoroso michael | acquired | 100,008 | 12.00 | 8,334 | president and ceo |
May 08, 2024 | scimeca dario | acquired | 9,996 | 12.00 | 833 | general counsel and secretary |
May 04, 2024 | brown melinda | acquired | - | - | 4,202 | - |
May 04, 2024 | wadsworth samuel c. | acquired | - | - | 4,202 | - |
May 04, 2024 | frankel stanley | acquired | - | - | 4,202 | - |
May 04, 2024 | buehler kevin | acquired | - | - | 4,202 | - |
May 04, 2024 | germano geno j | acquired | - | - | 4,202 | - |
May 04, 2024 | pire shari lisa | acquired | - | - | 4,202 | - |
Which funds bought or sold DTIL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | BARCLAYS PLC | sold off | -100 | -78,000 | - | -% |
May 15, 2024 | Aquilo Capital Management, LLC | new | - | 5,226,570 | 5,226,570 | 3.92% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 5,275 | 5,275 | -% |
May 15, 2024 | Alyeska Investment Group, L.P. | new | - | 3,390,000 | 3,390,000 | 0.02% |
May 15, 2024 | AMUNDI | sold off | -100 | -112,020 | - | -% |
May 15, 2024 | Blue Owl Capital Holdings LP | new | - | 274,183 | 274,183 | 0.06% |
May 15, 2024 | STATE STREET CORP | sold off | -100 | -89,187 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 385,280 | 385,280 | -% |
May 15, 2024 | MORGAN STANLEY | new | - | 159,452 | 159,452 | -% |
May 15, 2024 | Royal Bank of Canada | new | - | - | - | -% |
Unveiling Precision BioSciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Precision BioSciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Precision BioSciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 149.8% | 17,584 | 7,038 | 13,120 | 19,789 | 8,780 | 10,598 | 7,363 | 3,820 | 3,317 | 6,339 | 24,036 | 68,805 | 16,349 | 8,846 | 7,363 | 1,078 | 6,998 | 6,522 | 4,865 | 5,389 | 5,462 |
Operating Expenses | 82.3% | 21,771 | 11,944 | 25,483 | 31,776 | 33,244 | 12,024 | 22,039 | 33,374 | 30,652 | 37,063 | 35,578 | 47,173 | 35,091 | 32,326 | 33,407 | 33,886 | 34,494 | 28,383 | 26,843 | 29,260 | 24,956 |
S&GA Expenses | -100.0% | - | 8,539 | 9,633 | 9,830 | 11,086 | 9,955 | 10,281 | 10,438 | 10,680 | 10,593 | 9,638 | 9,938 | 9,498 | 9,200 | 8,534 | 8,703 | 9,615 | 8,479 | 7,052 | 6,500 | 4,995 |
R&D Expenses | 291.9% | 13,343 | 3,405 | 15,850 | 21,946 | 22,158 | 2,070 | 11,758 | 22,936 | 19,972 | 26,470 | 25,940 | 37,235 | 25,593 | 23,126 | 24,873 | 25,183 | 24,879 | 19,904 | 19,791 | 22,760 | 19,961 |
Interest Expenses | -0.9% | 574 | 579 | 576 | 553 | 522 | 486 | 405 | 178 | 42.00 | 53.00 | 55.00 | 24.00 | - | - | - | - | - | - | - | - | 182 |
Net Income | 152.7% | 8,588 | -16,289 | -8,079 | -11,891 | -25,060 | -28,488 | -23,946 | -31,035 | -28,168 | -22,290 | -11,279 | 21,656 | -18,689 | -23,453 | -26,016 | -32,701 | -26,836 | -20,916 | -20,742 | -19,436 | -31,783 |
Net Income Margin | 61.8% | -0.48* | -1.26* | -1.41* | -1.92* | -3.55* | -4.45* | -5.06* | -2.47* | -0.39* | -0.26* | -0.27* | -0.46* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -125.3% | -18,981 | -8,423 | -23,093 | -21,134 | -31,464 | -21,843 | 29,186 | -24,224 | -28,872 | -23,681 | -23,905 | -31,339 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 15.6% | 185 | 160 | 164 | 182 | 205 | 238 | 272 | 297 | 181 | 211 | 227 | 230 | 262 | 150 | 169 | 184 | 214 | 235 | 260 | 272 | 167 |
Current Assets | 17.9% | 161 | 136 | 146 | 148 | 169 | 199 | 225 | 248 | 134 | 162 | 183 | 188 | 219 | 106 | 123 | 137 | 167 | 194 | 220 | 237 | 137 |
Cash Equivalents | 18.1% | 138 | 117 | 122 | 138 | 158 | 190 | 212 | 184 | 116 | 144 | 160 | 174 | 193 | 90.00 | 104 | 127 | 154 | 181 | 206 | 226 | 116 |
Net PPE | -16.6% | 5.00 | 6.00 | 9.00 | 18.00 | 19.00 | 12.00 | 22.00 | 23.00 | 24.00 | 25.00 | 32.00 | 33.00 | 34.00 | 35.00 | 36.00 | 38.00 | 39.00 | 40.00 | 39.00 | 33.00 | 28.00 |
Liabilities | 4.7% | 148 | 141 | 135 | 148 | 164 | 178 | 187 | 194 | 112 | 120 | 126 | 130 | 203 | 106 | 105 | 99.00 | 99.00 | 97.00 | 105 | 98.00 | 156 |
Current Liabilities | -33.3% | 33.00 | 50.00 | 51.00 | 56.00 | 47.00 | 60.00 | 61.00 | 54.00 | 29.00 | 36.00 | 36.00 | 36.00 | 64.00 | 43.00 | 42.00 | 34.00 | 24.00 | 27.00 | 24.00 | 16.00 | 71.00 |
Long Term Debt | - | - | - | - | - | 22.00 | 22.00 | 22.00 | 22.00 | 2.00 | 2.00 | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | 97.3% | 37.00 | 19.00 | 29.00 | 34.00 | 40.00 | 60.00 | 84.00 | 103 | 70.00 | 91.00 | 101 | 101 | 59.00 | 44.00 | 64.00 | 86.00 | 115 | 138 | 156 | 174 | 11.00 |
Retained Earnings | 1.8% | -481 | -489 | -473 | -465 | -453 | -428 | -399 | -375 | -344 | -316 | -294 | -283 | -304 | -286 | -262 | -236 | -203 | -177 | -156 | -135 | -115 |
Additional Paid-In Capital | 1.9% | 519 | 509 | 503 | 500 | 495 | 490 | 485 | 480 | 415 | 409 | 397 | 385 | 365 | 331 | 327 | 323 | 320 | 316 | 313 | 310 | 128 |
Shares Outstanding | 66.1% | 7.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 59.00 | - | - | - | 170 | - | - | - | 664 | - | - | - | 383 | - | - | - | 589 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -125.3% | -18,981 | -8,423 | -23,093 | -21,134 | -31,464 | -21,843 | 29,186 | -24,224 | -28,872 | -23,681 | -23,905 | -31,339 | 68,072 | -13,452 | -22,223 | -25,801 | -25,910 | -20,556 | -13,977 | -16,575 | -19,907 |
Share Based Compensation | -2.1% | 2,906 | 2,969 | 3,105 | 3,874 | 4,092 | 4,536 | 5,133 | 5,138 | 4,390 | 4,435 | 4,551 | 3,896 | 3,632 | 3,854 | 3,709 | 3,118 | 3,105 | 2,621 | 2,491 | 2,279 | 1,549 |
Cashflow From Investing | -161.9% | -26.00 | 42.00 | 7,564 | -1,056 | -721 | -632 | -1,090 | -779 | -818 | -1,505 | -1,483 | -1,690 | -1,125 | -1,096 | -1,047 | -1,785 | -1,103 | -5,529 | -5,918 | -8,137 | -5,082 |
Cashflow From Financing | 1317.8% | 40,095 | 2,828 | -34.00 | 1,852 | 741 | - | -180 | 92,916 | 2,249 | 8,378 | 11,916 | 13,512 | 36,715 | 198 | 532 | 285 | 314 | 706 | 61.00 | 134,312 | 38,295 |
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenue | $ 17,584 | $ 8,780 |
Operating expenses | ||
Research and development | 13,343 | 11,048 |
General and administrative | 8,428 | 11,086 |
Total operating expenses | 21,771 | 22,134 |
Operating loss | (4,187) | (13,354) |
Other income (expense): | ||
Gain (loss) from equity method investment | 1,713 | (1,341) |
Loss on changes in fair value | (348) | (769) |
Gain on change in fair value of warrant liability | 10,386 | |
Interest expense | (574) | (522) |
Interest income | 1,663 | 2,043 |
Loss on disposal of assets | (65) | (7) |
Total other income (expense) | 12,775 | (596) |
Income (loss) from continuing operations | 8,588 | (13,950) |
Loss from discontinued operations | (11,110) | |
Net income (loss) | $ 8,588 | $ (25,060) |
Net income (loss) per share - Basic | $ 1.7 | $ (6.75) |
Net income (loss) per share - Diluted | $ 1.7 | $ (6.75) |
Weighted average common shares outstanding - Basic | 5,060,978 | 3,709,894 |
Weighted average common shares outstanding - Diluted | 5,063,406 | 3,709,894 |
CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 137,766 | $ 116,678 |
Accounts receivable | 390 | 901 |
Prepaid expenses | 9,254 | 5,977 |
Convertible note receivable | 11,553 | 11,897 |
Assets held for sale | 378 | 487 |
Contract asset | 1,359 | |
Other current assets | 128 | 419 |
Total current assets | 160,828 | 136,359 |
Property, equipment, and software—net | 5,286 | 6,338 |
Intangible assets—net | 386 | 400 |
Right-of-use assets—net | 7,979 | 8,263 |
Investment in equity securities | 3,206 | 3,206 |
Note receivable—net | 6,818 | 4,990 |
Other assets | 238 | 225 |
Total assets | 184,741 | 159,781 |
Current liabilities: | ||
Accounts payable | 1,136 | 2,968 |
Accrued compensation | 1,220 | 4,978 |
Accrued research and development expenses | 656 | 1,557 |
Deferred revenue | 2,406 | 12,035 |
Loan payable-net | 22,460 | 22,412 |
Lease liabilities | 1,182 | 1,133 |
Other current liabilities | 2,772 | 2,391 |
Current liabilities of discontinued operations | 1,506 | 2,513 |
Total current liabilities | 33,338 | 49,987 |
Deferred revenue | 74,766 | 73,082 |
Lease liabilities | 7,411 | 7,723 |
Warrant liability | 22,020 | |
Contract liabilities | 10,000 | 10,000 |
Noncurrent liabilities of discontinued operations | 128 | |
Total liabilities | 147,535 | 140,920 |
Commitments and contingencies (Note 4) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value- 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Common stock; $0.000005 par value - 200,000,000 shares authorized as of March 31, 2024 and December 31,2023; 6,943,254 shares issued and 6,916,239 shares outstanding as of March 31, 2024; 4,191,053 shares issued and 4,164,038 shares outstanding as of December 31, 2023 | 1 | 1 |
Additional paid-in capital | 519,200 | 509,443 |
Accumulated deficit | (481,043) | (489,631) |
Treasury stock | (952) | (952) |
Total stockholders’ equity | 37,206 | 18,861 |
Total liabilities and stockholders’ equity | $ 184,741 | $ 159,781 |